Your Health, We Care
In multiple clinical trials, Ceritinib has shown significant efficacy. In the ASCEND-4 trial, the median progression free survival (PFS) of patients treated with Ceritinib was 16.6 months, while the PFS of patients receiving chemotherapy was only 8.1 months, indicating that Ceritinib has a significant advantage in delaying disease progression.
In addition, Ceritinib has been shown to be effective in treating ALK positive NSCLC patients who develop resistance or intolerance to crizotinib, providing a new treatment option for these patients.
